Cargando…

P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)

Detalles Bibliográficos
Autores principales:	Atallah, Ehab, Mauro, Michael, Sasaki, Koji, Yair Levy, Moshe, Koller, Paul, Sadek, Islam, Yang, Daisy, Ruckel-Kumar, Julie, Khan, Mahmudul, Cortes, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428989/ http://dx.doi.org/10.1097/01.HS9.0000969656.81442.84

Ejemplares similares

P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
por: Hughes, Timothy, et al.
Publicado: (2023)

PB1980: ASC4KIDS: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
por: Hijiya, Nobuko, et al.
Publicado: (2023)

S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
por: Čuřík, Nikola, et al.
Publicado: (2023)

P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
por: Breccia, Massimo, et al.
Publicado: (2023)

P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA
por: Atallah, Ehab, et al.
Publicado: (2023)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
por: Kuzmina, Elena, et al.
Publicado: (2023)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hughes, T., et al.
Publicado: (2022)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
por: Atallah, Ehab, et al.
Publicado: (2023)

PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS
por: Breccia, M., et al.
Publicado: (2022)

PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hijiya, N., et al.
Publicado: (2022)

Escales 2 : methode de francais /
por: Blanc, Jacques
Publicado: (2001)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

Escalation strategies for combination therapy Phase I trials
por: Sweeting, Michael J, et al.
Publicado: (2012)

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose‐Escalation Multicenter Study
por: Jankovic, Joseph, et al.
Publicado: (2018)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
por: Krawczyk, Natalia, et al.
Publicado: (2022)

Real de-escalation or escalation in disguise?
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2023)

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
por: Yuda, Junichiro, et al.
Publicado: (2022)

Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
por: Réa, Delphine, et al.
Publicado: (2023)

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
por: Bueno Muiño, Coralia, et al.
Publicado: (2022)

Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence
por: Ezard, Nadine, et al.
Publicado: (2016)

Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study
por: Ezard, Nadine, et al.
Publicado: (2021)

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
por: Isfort, Susanne, et al.
Publicado: (2023)

Dose Escalation Methods in Phase I Cancer Clinical Trials
por: Le Tourneau, Christophe, et al.
Publicado: (2009)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

The Role of Early Molecular Response in the Management of Chronic Phase CML
por: Harrington, Patrick, et al.
Publicado: (2017)

Phase I dose‐escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer
por: Masuda, Takaaki, et al.
Publicado: (2020)

Escalating SARS-CoV-2 circulation in environment and tracking waste management in South Asia
por: Islam, Ariful, et al.
Publicado: (2021)

Treatment-Free Remission: the New Goal in CML Therapy
por: Atallah, Ehab, et al.
Publicado: (2021)

Phase I Dose-Escalation Study of Nimustine in Tumor-Bearing Dogs
por: TAKAHASHI, Masashi, et al.
Publicado: (2014)

Phase I dose-escalation oncology trials with sequential multiple schedules
por: Günhan, Burak Kürsad, et al.
Publicado: (2021)

Escalation and de-escalation of mechanical circulatory support in cardiogenic shock
por: Bertoldi, Letizia F, et al.
Publicado: (2021)

Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
por: Padala, Sandeep, et al.
Publicado: (2023)

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
por: Phatak, Pradyumna, et al.
Publicado: (2010)

SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma
por: Ashton, M., et al.
Publicado: (2017)

Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
por: Kudo, Toshihiro, et al.
Publicado: (2020)

Escalating burden of SARS-CoV-2 infection in Ethiopia
por: Adane, Kelemework, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mhcmiad81qsktdqprg82j1pao8